Current immunotherapeutic strategies in colon cancer.

Published

Journal Article (Review)

Because chemotherapy is standard in the treatment of colorectal cancer, it is important to demonstrate whether immunizations may be given to patients receiving systemic chemotherapy. Although some studies have demonstrated immune responses in patients with metastatic colorectal carcinoma who failed standard chemotherapy, the setting of minimal residual disease may be the preferred setting for cancer vaccines. It may be important to choose antigens that have functions important to the cancer cell. The best adjuvant is not well established and may depend on the type of immune response desired. The immune system is "programmed" to down-regulate immune responses once they have become activated to avoid the development of autoimmune disease.

Full Text

Duke Authors

Cited Authors

  • Morse, M; Langer, L; Starodub, A; Hobeika, A; Clay, T; Lyerly, HK

Published Date

  • October 2007

Published In

Volume / Issue

  • 16 / 4

Start / End Page

  • 873 - x

PubMed ID

  • 18022550

Pubmed Central ID

  • 18022550

International Standard Serial Number (ISSN)

  • 1055-3207

Digital Object Identifier (DOI)

  • 10.1016/j.soc.2007.07.005

Language

  • eng

Conference Location

  • United States